John D. Buynak

John D. Buynak

Auto-generated profile, based on publicly available information

John D. Buynak

Department of Chemistry, Southern Methodist University

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

7 September 2010 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
GBGermán Bou
Germán Bou
ESElena Santillana
Elena Santillana
ASAnjaneyulu Sheri
Anjaneyulu Sheri
ABAlejandro Beceiro
Alejandro Beceiro
JSJared M. Sampson
Jared M. Sampson
JBJohn D. Buynak
John D. Buynak

23 August 2013 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
JBJohn D Buynak
John D Buynak
Introduction: New β-lactamases with ever-broadening substrate specificity are rapidly disseminating globally, thereby threatening the efficacy of our best β-lactam antibiotics. A potential solution to this problem is the development of wide-spectrum β-lactamase inhibitors, to be coadministered with existing and new β-lactams. Areas covered: This review covers the patent literature in the β-lactamase inhibitor area roughly from 2010 to 2013, with prior background being provided in the cases of key inhibitors and antibiotic/inhibitor combinations. An effort has been made to identify the strong and weak points of each inhibitor and combination. Expert opinion: Research in this field has become increasingly diverse, with several non-β-lactam inhibitor classes now assuming importance. The emphasis has been on finding inhibitors of AmpC, the extended-spectrum β-lactamases and class A and D carbapenemases that can demonstrate synergy with antibiotics against resistant Gram-negative pathogens. Progress has been made. Metallo-β-lactamases (MBL)-mediated resistance, however, represents an unmet challenge. The author believes that it will be extremely difficult to generate a selective, commercially viable MBL inhibitor with sufficient activity against NDM-1 and that alternate design strategies will need to be employed.

1 April 2010 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
SDSarah M. Drawz
Sarah M. Drawz
CBChristopher R. Bethel
Christopher R. Bethel
VDVenkata R. Doppalapudi
Venkata R. Doppalapudi
ASAnjaneyulu Sheri
Anjaneyulu Sheri
SPSundar Ram Reddy Pagadala
Sundar Ram Reddy Pagadala
Robert BonomoRobert Bonomo
Robert Bonomo
OXA β-lactamases are largely responsible for β-lactam resistance inAcinetobacterspp. andPseudomonas aeruginosa, two of the most difficult-to-treat nosocomial pathogens. In general, the β-lactamase inhibitors used in clinical practice (clavulanic acid, sulbactam, and tazobactam) demonstrate poor activity against class D β-lactamases. To overcome this challenge, we explored the abilities of β-lactamase inhibitors of the C-2- and C-3-substituted penicillin and cephalosporin sulfone families against OXA-1, extended-spectrum (OXA-10, OXA-14, and OXA-17), and carbapenemase-type (OXA-24/40) class D β-lactamases. Three C-2-substituted penicillin sulfone compounds (JDB/LN-1-255, JDB/LN-III-26, and JDB/ASR-II-292) showed lowKivalues for the OXA-1 β-lactamase (0.70 ± 0.14 → 1.60 ± 0.30 μM) and demonstrated significantKiimprovements compared to the C-3-substituted cephalosporin sulfone (JDB/DVR-II-214), tazobactam, and clavulanic acid. The C-2-substituted penicillin sulfones JDB/ASR-II-292 and JDB/LN-1-255 also demonstrated lowKis for the OXA-10, -14, -17, and -24/40 β-lactamases (0.20 ± 0.04 → 17 ± 4 μM). Furthermore, JDB/LN-1-255 displayed stoichiometric inactivation of OXA-1 (the turnover number, i.e., the partitioning of the initial enzyme inhibitor complex between hydrolysis and enzyme inactivation [tn] = 0) andtns ranging from 5 to 8 for the other OXA enzymes. Using mass spectroscopy to study the intermediates in the inactivation pathway, we determined that JDB/LN-1-255 inhibited OXA β-lactamases by forming covalent adducts that do not fragment. On the basis of the substrate and inhibitor kinetics of OXA-1, we constructed a model showing that the C-3 carboxylate of JDB/LN-1-255 interacts with Ser115 and Thr213, the R-2 group at C-2 fits between the space created by the long B9 and B10 β strands, and stabilizing hydrophobic interactions are formed between the pyridyl ring of JDB/LN-1-255 and Val116 and Leu161. By exploiting conserved structural and mechanistic features, JDB/LN-1-255 is a promising lead compound in the quest for effective inhibitors of OXA-type β-lactamases.

1 March 2009 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
SGSudhakar Reddy Ganta
Sudhakar Reddy Ganta
SPSenthil Perumal
Senthil Perumal
SPSundar Ram Reddy Pagadala
Sundar Ram Reddy Pagadala
ØSØrjan Samuelsen
Ørjan Samuelsen
JSJames Spencer
James Spencer
JBJohn D. Buynak
John D. Buynak